Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04545008 · ClinicalTrials.gov registry record · Phase 1
Trial of Famotidine & N-Acetyl Cysteine for Outpatients With COVID-19
A Phase 1 study, sponsored by Prisma Health-Upstate.
- Terminated
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT04545008 is a Phase 1 study that was terminated before completion, run by Prisma Health-Upstate. The registered enrollment target is 2 participants.
The verdict
NCT04545008, a Phase 1 study, was terminated before completion, sponsored by Prisma Health-Upstate.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
The purpose of this trial is to assess the safety and toxicity profile of the combination of famotidine and oral n-acetyl cysteine in adult outpatients with newly diagnosed SARS-CoV-2 infection.
Interventions
- DRUG Famotidine
- DRUG N-Acetyl cysteine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2020-10-20 |
| Est. Completion | 2021-06-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04545008
The ClinicalTrials.gov registry entry for NCT04545008 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Prisma Health-Upstate, which has 67 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Famotidine is the first listed.
NCT04545008 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04545008 about?
NCT04545008 is a clinical study titled "Trial of Famotidine & N-Acetyl Cysteine for Outpatients With COVID-19". The purpose of this trial is to assess the safety and toxicity profile of the combination of famotidine and oral n-acetyl cysteine in adult outpatients with newly diagnosed SARS-CoV-2 infection.
What is the current status of trial NCT04545008?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2020-10-20. Estimated completion is 2021-06-02.
What interventions are being tested in trial NCT04545008?
The interventions under investigation include: Famotidine (DRUG), N-Acetyl cysteine (DRUG).
Who is sponsoring clinical trial NCT04545008?
This trial is sponsored by Prisma Health-Upstate, which has 67 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.